Treatment of Type 2 Diabetes Mellitus Patients
US-2016296601-A1 · Oct 13, 2016 · US
Combination of an insulin and a GLP-1 agonist
US10117909B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10117909-B2 |
| Application number | US-201615340969-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 1, 2016 |
| Priority date | Oct 17, 2008 |
| Publication date | Nov 6, 2018 |
| Grant date | Nov 6, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to a drug comprising at least one insulin and at least one GLP-1 receptor agonist.
First claim
Opening claim text (preview).
The invention claimed is: 1. A prefilled syringe comprising a pharmaceutical formulation, wherein the pharmaceutical formulation comprises a combination of: (a) insulin glargine or a pharmaceutically acceptable salt thereof, and (b) desPro 36 exendin-4(1-39)-Lys 6 -NH 2 (AVE0010) or a pharmaceutically acceptable salt thereof; wherein the pharmaceutical formulation has a concentration of insulin glargine that is about 100 units/mL and a concentration of AVE0010 that is about 33 μg/mL; and wherein the prefilled syringe is configured to administer the pharmaceutical formulation at a dosage of insulin glargine between about 15 units and about 80 units and a dosage of AVE0010 between about 5 μg and about 2 mg. 2. The prefilled syringe of claim 1 , wherein the prefilled syringe is configured to administer the pharmaceutical formulation at a dosage of insulin glargine between about 15 units and about 60 units and a dosage of AVE0010 between about 5 μg and about 20 μg. 3. The prefilled syringe of claim 1 , wherein the prefilled syringe is configured to administer the pharmaceutical formulation at a dosage of insulin glargine between about 15 units and about 80 units and a dosage of AVE0010 between about 5 μg and about 20 μg. 4. A prefilled syringe comprising a pharmaceutical formulation, wherein the pharmaceutical formulation comprises a combination of: (a) insulin glargine or a pharmaceutically acceptable salt thereof, and (b) desPro 36 exendin-4(1-39)-Lys 6 -NH 2 (AVE0010) or a pharmaceutically acceptable salt thereof; wherein the pharmaceutical formulation has a concentration of insulin glargine that is about 100 units/mL and a concentration of AVE0010 that is about 20 m/ml to about 150 μg/ml. 5. The prefilled syringe of claim 4 , wherein the pharmaceutical formulation has a concentration of insulin glargine that is about 100 units/mL and a concentration of AVE0010 that is about 25, 33, 40, 66, or 75m/mL. 6. The prefilled syringe of claim 4 , wherein the pharmaceutical formulation has a concentration of insulin glargine that is about 100 units/mL and a concentration of AVE0010 that is about 33 μg/mL. 7. A prefilled syringe comprising a pharmaceutical formulation, wherein the pharmaceutical formulation comprises a combination of: (a) insulin glargine or a pharmaceutically acceptable salt thereof, and (b) desPro 36 exendin-4(1-39)-Lys 6 -NH 2 (AVE0010) or a pharmaceutically acceptable salt thereof; wherein the pharmaceutical formulation has a concentration of insulin glargine that is about 100 units/mL, and wherein the ratio of insulin glargine and AVE0010 in the pharmaceutical formulation is about 1.5 units to about 4 units of insulin glargine to 1 μg of AVE0010. 8. The prefilled syringe of claim 7 , wherein the ratio of insulin glargine and AVE0010 in the pharmaceutical formulation is about 3 units of insulin glargine to 1 μg of AVE0010.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
for glucose homeostasis (pancreatic hormones A61P5/48) · CPC title
for hyperglycaemia, e.g. antidiabetics · CPC title
for increasing or potentiating the activity of insulin · CPC title
Drugs for disorders of the endocrine system · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10117909B2 cover?
- The invention relates to a drug comprising at least one insulin and at least one GLP-1 receptor agonist.
- Who is the assignee on this patent?
- Sanofi Aventis Deutschland
- What technology area does this patent fall under?
- Primary CPC classification A61K38/26. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).